List of Tables
- Table 2-01. Information necessary for a risk assessment during pretravel consultations
- Table 2-02. Vaccines to update or consider during pretravel consultations
- Table 2-03. Major topics for discussion during pretravel consultations
- Table 2-04. Recommended intervals between administration of antibody-containing products and measles-containing vaccine or varicella-containing vaccine
- Table 2-05. Recommended and minimum ages and intervals vaccine doses
- Table 2-06. Categories of recommendations for yellow fever (YF) vaccination
- Table 2-07. Comparison of water disinfection techniques
- Table 2-08. Microorganism size and susceptibility to filtration
- Table 2-09. Summary of field water disinfection techniques
- Table 2-10. Travelers’ diarrhea treatment recommendations
- Table 2-11. Acute diarrhea antibiotic treatment recommendations
- Table 3-01. Air quality index
- Table 3-02. Strategies to mitigate adverse health effects of air pollution
- Table 3-03. Common reservoirs of zoonotic diseases and mechanisms/routes of human infection
- Table 3-04. Risk categories for acute mountain sickness
- Table 3-05. Ascent risk associated with various underlying medical conditions
- Table 3-06. Recommended medication dosing to prevent and treat altitude illness
- Table 4-01. Mechanism of pathogenesis and typical clinical syndrome of Escherichia coli pathotypes
- Table 4-02. Vaccines to prevent hepatitis A
- Table 4-03. Interpretation of serologic test results for hepatitis B virus infection
- Table 4-04. Vaccines to prevent hepatitis B
- Table 4-05. Recommended dosage and duration of antiviral medications for treatment and prophylaxis of influenza A and B
- Table 4-06. Vaccine to prevent Japanese encephalitis (JE)
- Table 4-07. Risk areas and transmission season for Japanese encephalitis (JE), by country
- Table 4-08. Reliable supply regimens for malaria treatment
- Table 4-09. Considerations when choosing a drug for malaria prophylaxis
- Table 4-10. Drugs used in the prophylaxis of malaria
- Table 4-11. Half-lives of malaria prophylaxis drugs
- Table 4-12. Changing medications as a result of side effects during malaria chemoprophylaxis
- Table 4-13. Food and Drug Administration recommendations for deferring blood donation in people returning from malarious areas
- Table 4-14. Meningococcal vaccines licensed and available in the United States
- Table 4-15. Alternative adult polio vaccine regimens
- Table 4-16. Criteria for preexposure immunization for rabies
- Table 4-17. Preexposure immunization for rabies
- Table 4-18. Postexposure immunization for rabies
- Table 4-19. Classification, primary arthropod vector, and host association of Rickettsiales known to cause disease in humans
- Table 4-20. Clinical characteristics of smallpox, monkeypox, cowpox, vaccinia (naturally occurring), and other similar orthopoxviruses
- Table 4-21. Estimated proportion of MDR TB cases in high MDR TB burden countries, 2016
- Table 4-22. Vaccines to prevent typhoid fever
- Table 4-23. Countries with risk of yellow fever (YF) virus transmission
- Table 4-24. Countries with low potential for exposure to yellow fever (YF) virus
- Table 4-25. Vaccine to prevent yellow fever (YF)
- Table 4-26. Contraindications and precautions to yellow fever vaccine administration
- Table 4-27. Countries that require proof of yellow fever (YF) vaccination from all arriving travelers
- Table 5-01. Immunization of immunocompromised adults
- Table 5-02. Immunosuppressive/ immunomodulatory biologic agents that preclude use of live vaccines
- Table 5-03. Special considerations for travelers with chronic medical illnesses
- Table 6-01. Coverage requirements, potential exclusions, and preexisting medical conditions: questions travelers should consider asking their insurance company when deciding whether to purchase supplemental insurance coverage
- Table 8-01. Twenty-nine most visited destinations for US citizens traveling abroad, 2015–2016: WHO estimated crash death rate (per 100,000 population) and number of US citizen crash deaths per country
- Table 8-02. Recommended strategies to reduce road traffic crashes and injuries while abroad
- Table 9-01. Types of international business travelers (IBTs)
- Table 9-02. Online health and safety information resources for study abroad students
- Table 9-03. Diseases for which VFR travelers are at increased risk, proposed reasons for risk variance, and recommendations to reduce risks
- Table 9-04. International mass gathering events, 2019–2022
- Table 11-01. Common travel- related infections by incubation period
- Table 11-02. Considerations for screening asymptomatic travelers
- Table 11-03. Common causes of fever in the tropics, by geographic area
- Table 11-04. Clinical findings and select associated infectious diseases
- Table 11-05. Selected rapid diagnostic tests for pathogens in the returning traveler
- Table 11-06. Epidemiology and clinical manifestations of common STIs
- Table 11-07. Ten most common skin lesions in returned travelers, by cause
- Table 11-08. Recommended new arrival laboratory screening tests for immigrants receiving medical care in the United States
- Table B-01. Travel vaccine summary
Page last reviewed: December 18, 2020